Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22700990
DOI
10.1093/annonc/mds145
PII: S0923-7534(19)37475-7
Knihovny.cz E-resources
- MeSH
- Exanthema chemically induced MeSH
- Phenylurea Compounds adverse effects therapeutic use MeSH
- Indoles adverse effects therapeutic use MeSH
- Angiogenesis Inhibitors adverse effects therapeutic use MeSH
- Protein Kinase Inhibitors adverse effects therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy mortality MeSH
- Skin drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Kidney Neoplasms drug therapy mortality MeSH
- Niacinamide adverse effects analogs & derivatives therapeutic use MeSH
- Disease-Free Survival MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Pyrroles adverse effects therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Sorafenib MeSH
- Sunitinib MeSH
- Hand-Foot Syndrome MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Phenylurea Compounds MeSH
- Indoles MeSH
- Angiogenesis Inhibitors MeSH
- Protein Kinase Inhibitors MeSH
- Niacinamide MeSH
- Antineoplastic Agents MeSH
- Pyrroles MeSH
- Sorafenib MeSH
- Sunitinib MeSH
BACKGROUND: A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed. PATIENTS AND METHODS: Data on mRCC patients treated with sunitinib or sorafenib were obtained from the Czech Clinical Registry of Renal Cell Cancer Patients. Outcomes of patients who developed hand-foot syndrome (HFS) of any grade and/or grade 3/4 rash during the treatment were compared with patients without HFS and no, mild, or moderate rash. RESULTS: The cohort included 705 patients treated with sunitinib and 365 patients treated with sorafenib. For sunitinib, the median overall survival (OS) was 43.0 months versus 31.0 months (P = 0.027) and median progression-free survival (PFS) 20.8 months versus 11.1 months (P = 0.007) for patients with versus without dermatologic toxicity, respectively. For sorafenib, the median OS and PFS were 27.9 and 24.6 months (P = 0.244), and 12.2 and 8.8 months (P = 0.050), respectively. In multivariable Cox regression, the skin toxicity was significantly associated with longer OS in the sunitinib cohort. CONCLUSION: The presence of skin toxicity is associated with improved OS and PFS in patients with mRCC treated with sunitinib.
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
Masaryk Memorial Cancer Institute of Oncology Brno Czech Republic
References provided by Crossref.org
Neopterin as a biomarker of immune response in cancer patients
